Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biohaven (BHVN) Research & Development (2021 - 2026)

Biohaven has reported Research & Development over the past 6 years, most recently at $103.8 million for Q1 2026.

  • Quarterly results put Research & Development at $103.8 million for Q1 2026, down 44.65% from a year ago — trailing twelve months through Mar 2026 was $272.0 million (down 67.13% YoY), and the annual figure for FY2025 was $635.1 million, down 20.21%.
  • Research & Development reached $103.8 million in Q1 2026 per BHVN's latest filing, up from $12.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $314.8 million in Q2 2024 and bottomed at $4.2 million in Q4 2022.
  • Median Research & Development over the past 5 years was $103.8 million (2026), compared with a mean of $113.7 million.
  • The largest annual shift saw Research & Development skyrocketed 3075.81% in 2023 before it crashed 95.24% in 2025.
  • Over 5 years, Research & Development stood at $4.2 million in 2022, then surged by 3075.81% to $134.8 million in 2023, then rose by 24.23% to $167.5 million in 2024, then crashed by 92.83% to $12.0 million in 2025, then skyrocketed by 765.22% to $103.8 million in 2026.
  • Business Quant data shows Research & Development for BHVN at $103.8 million in Q1 2026, $12.0 million in Q4 2025, and $141.2 million in Q3 2025.